Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- IgG Antibodies, PD-1/PD-L1 Inhibitors, Anti-inflammatory mAbs
- Countries
- 6
01
Overview
A Phase 2 trial of eltrekibart in hidradenitis suppurativa (HS), sponsored by Eli Lilly and Company. Started Oct 2023; status: completed.
02
Drugs
eltrekibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06046729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046729.